

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Mammalian target of rapamycin (mTOR; FRAP; RAFT1); Ras; heat shock protein 90 (Hsp90)	<p>Studies in mice suggest combining Hsp90 and mTOR inhibitors could help treat Ras-driven cancers. In a mouse model of malignant peripheral nerve sheath tumors, rapamycin plus the Hsp90 inhibitor retaspimycin decreased tumor size compared with either compound alone. In a mouse model of Ras-driven non-small cell lung cancer (NSCLC), the two compounds reduced tumor size compared with either agent alone. Next steps could include evaluating the combination in clinical trials.</p> <p>Retaspimycin (IPI-504) from Infinity Pharmaceuticals Inc. is in Phase II testing to treat breast cancer and advanced NSCLC and is in Phase I testing to treat advanced solid tumors.</p> <p><b>SciBX 4(40); doi:10.1038/scibx.2011.1109</b> Published online Oct. 13, 2011</p>	Patent and licensing status unavailable	<p>De Raedt, T. <i>et al. Cancer Cell</i>; published online Sept. 13, 2011; doi:10.1016/j.ccr.2011.08.014</p> <p><b>Contact:</b> Karen Cichowski, Brigham and Women's Hospital, Boston, Mass. e-mail: <a href="mailto:kcichowski@rics.bwh.harvard.edu">kcichowski@rics.bwh.harvard.edu</a></p>